REAL-WORLD COMPARISON OF HEALTHCARE RESOURCE UTILIZATION AND COSTS BETWEEN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH FIRST-LINE IBRUTINIB OR ACALABRUTINIB

被引：0
|
作者：
Rogers, K. A. [1 ]
Qureshi, Z. P. [2 ]
Ding, Z. [2 ]
Emond, B. [3 ]
Gogna, P. [3 ]
Lafeuille, M. H. [3 ]
Bokun, A. [2 ]
Fradley, M. [4 ,5 ]
机构：
[1] Ohio State Univ, Div Hematol, Columbus, OH USA
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Hosp Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Thalheimer Ctr Cardiooncol, Philadelphia, PA USA
[5] Hosp Univ Penn, Perelman Sch Med, Div Cardiol, Philadelphia, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE70
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [21] Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib
    Jacobs, Ryan
    Lu, Xiaoxiao
    Emond, Bruno
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Khan, Wasiulla
    Wu, Linda
    Qureshi, Zaina P.
    Levy, Moshe Yair
    [J]. BLOOD, 2022, 140 : 1931 - 1933
  • [22] Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
    Aarup, Kathrine
    Enggaard, Lisbeth
    Pedersen, Robert Schou
    Thomsen, Rasmus Heje
    Bergmann, Olav Jonas
    Frederiksen, Mikael
    Christiansen, Ilse
    Nielsen, Tine
    Frederiksen, Henrik
    Niemann, Carsten Utoft
    Andersen, Michael Asger
    [J]. BLOOD, 2019, 134
  • [23] Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Front-Line Ibrutinib or Chemoimmunotherapy
    Nabhan, Chadi
    Chung, Jessica
    Mato, Anthony R.
    Kish, Jonathan
    Nero, Damion
    [J]. BLOOD, 2017, 130
  • [24] Real-World Evaluation of Treatment Discontinuation and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Chanan-Khan, Asher Alban
    Challagulla, Swetha
    Donckels, Elizabeth
    Chuang, Po-Ya
    Yang, Keri
    [J]. BLOOD, 2023, 142
  • [25] Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Philip Lee
    Kristin D. Kistler
    Luc Douyon
    Raisa Volodarsky
    Alex Young
    Sudeep Karve
    Swetha Challagulla
    [J]. Drugs - Real World Outcomes, 2023, 10 : 11 - 22
  • [26] Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Lee, Philip
    Kistler, Kristin D.
    Douyon, Luc
    Volodarsky, Raisa
    Young, Alex
    Karve, Sudeep
    Challagulla, Swetha
    [J]. DRUGS-REAL WORLD OUTCOMES, 2023, 10 (01) : 11 - 22
  • [27] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 : S170 - S170
  • [28] Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S330 - S330
  • [29] Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia
    Itchaki, Gilad
    Brown, Jennifer R.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (01) : 3 - 19
  • [30] REDUCED HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA ACHIEVING COMPLETE REMISSION TO FIRST-LINE THERAPY
    Enschede, S. Heitner
    Samp, J.
    Guerin, A.
    Foster, R.
    Meissner, B.
    Rokito, A.
    Gauthier, G.
    [J]. HAEMATOLOGICA, 2017, 102 : 425 - 426
12345